Aethlon Medical Secures $4.5 Million Funding for Clinical Expansion and Hemopurifier Development

Aethlon Medical Secures Funding for Expanding Clinical Initiatives

Aethlon Medical, Inc., a clinical-stage therapeutic company based in San Diego, announces a significant public offering aimed at enhancing its research capabilities. The company prices an offering of 5 million shares of common stock, or pre-funded warrants, along with warrants for an additional 5 million shares at $0.90 each. This initiative is expected to generate approximately $4.5 million in gross proceeds, which Aethlon plans to allocate towards general corporate purposes, including critical investments in clinical trials, research and development, and working capital. The offering, conducted under a registration statement effective as of September 4, 2024, is facilitated by Maxim Group LLC as the exclusive placement agent.

The primary focus of Aethlon Medical remains its innovative Hemopurifier, a device designed to selectively remove harmful pathogens from biological fluids, thereby addressing urgent needs in oncology and infectious diseases. The development and deployment of the Hemopurifier align with Aethlon's mission to enhance patient outcomes in areas with significant unmet medical needs. By securing additional funding, Aethlon aims to bolster its clinical initiatives, which are crucial for the advancement of the Hemopurifier and its potential applications. The anticipated closing of the offering around September 5, 2025, is contingent upon customary closing conditions, further emphasizing Aethlon's commitment to enhancing its therapeutic portfolio.

With the funding, Aethlon Medical is well-positioned to accelerate its clinical trials and research efforts, critical for the validation of its Hemopurifier technology. This funding is not only a financial boost but also a strategic move to position the company favorably within the competitive landscape of medical therapeutics, particularly in the fields of oncology and infectious disease management.

In addition to the funding announcement, Aethlon Medical continues to engage with potential investors through its prospectus available on the SEC's website. The company’s advancements in medical technology, particularly with the Hemopurifier, could pave the way for significant breakthroughs in treating diseases that currently pose substantial challenges to healthcare systems globally. Investors and stakeholders are encouraged to stay informed through Aethlon's official communications as the company progresses with its innovative solutions.